Sign In
Buy MITO
$0.320
+0 (+0%)
At Close: Feb 14, 2023
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced findings from two new interim analyses of data from the Phase 3 H
Hedge Funds Getting Interested In Stealth BioTherapeutics Corp (MITO)
10:40pm, Thursday, 04'th Jun 2020
In this article we will check out the progression of hedge fund sentiment towards Stealth BioTherapeutics Corp (NASDAQ:MITO) and determine whether it is a good investment right now. We at Insider Monk
Stealth BioTherapeutics to Present at Jefferies Virtual Healthcare Conference
08:30pm, Tuesday, 26'th May 2020
Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial
Stealth BioTherapeutics Corp (MITO) Shares March Higher, Can It Continue?
01:41pm, Thursday, 14'th May 2020
As of late, it has definitely been a great time to be an investor in Stealth BioTherapeutics Corp (MITO).
Stealth BioTherapeutics to Present at UBS Virtual Global Healthcare Conference
12:30pm, Wednesday, 13'th May 2020
Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial
Stealth BioTherapeutics Corp (MITO) CEO Reenie McCarthy on Q1 2020 Results - Earnings Call Transcript
01:12am, Wednesday, 13'th May 2020
Stealth BioTherapeutics Corp (NASDAQ:MITO) Q1 2020 Earnings Conference Call May 7, 2020 08:30 ET Company Participants Henry Hess - Chief Legal Counsel Reenie Mc
Stealth BioTherapeutics Corp (MITO) Q1 2020 Earnings Call Transcript
10:30pm, Friday, 08'th May 2020
Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of Stealth
Stealth BioTherapeutics Reports First Quarter 2020 Financial Results and Recent Business Highlights
11:30am, Thursday, 07'th May 2020
Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial
Stealth BioTherapeutics to Report First Quarter 2020 Financial Results on Thursday, May 7, 2020
10:00pm, Monday, 04'th May 2020
Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial
Stealth BioTherapeutics Corp (MITO) Shares March Higher, Can It Continue?
02:57pm, Wednesday, 22'nd Apr 2020
As of late, it has definitely been a great time to be an investor in Stealth BioTherapeutics Corp (MITO).
Stealth BioTherapeutics Corp (MITO) Shares March Higher, Can It Continue?
02:57pm, Wednesday, 22'nd Apr 2020
As of late, it has definitely been a great time to be an investor in Stealth BioTherapeutics Corp (MITO).
Stealth Biotherapeutics Announces $20 Million Financing to Advance Development of Elamipretide and Pipeline
12:25pm, Monday, 13'th Apr 2020
Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial d
Stealth BioTherapeutics Corp (NASDAQ:MITO) Given Average Rating of "Buy" by Brokerages
10:06am, Monday, 13'th Apr 2020
Stealth BioTherapeutics Corp (NASDAQ:MITO) has earned a consensus recommendation of “Buy” from the seven ratings firms that are covering the company, MarketBeat.com reports. Two analysts have rate
Stealth BioTherapeutics (NASDAQ:MITO) Trading 13% Higher
09:20am, Saturday, 11'th Apr 2020
Stealth BioTherapeutics Corp (NASDAQ:MITO) was up 13% on Thursday . The company traded as high as $1.74 and last traded at $1.56, approximately 316,522 shares were traded during mid-day trading. A dec
